Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s stock price dropped 9.5% during mid-day trading on Tuesday . The stock traded as low as $1.50 and last traded at $1.53. Approximately 23,196 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 31,001 shares. The stock had previously closed at $1.69.
Humacyte Stock Performance
The business’s 50 day simple moving average is $2.33 and its 200 day simple moving average is $1.57.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Recommended Stories
- Five stocks we like better than Humacyte
- Differences Between Momentum Investing and Long Term Investing
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Using the MarketBeat Dividend Yield Calculator
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
